Weight-Loss Drugs Enter Corporate Benefits as Employer Subsidies Rise

Brazilian corporate wellness firm Vidalink reports 93,979 purchases of weight-loss pens (Wegovy, Mounjaro, Ozempic) by employees across 200+ client companies over three years, signaling mainstream adoption of obesity drugs as a standard corporate benefit. The trend reflects growing employer investment in chronic-disease management, with potential implications for healthcare costs and pharmaceutical demand. Details on subsidy levels and cost-sharing remain undisclosed.